Literature DB >> 16012018

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.

Markus Bickel1, Christoph Stephan, Carsten Rottmann, Amina Carlebach, Anette Haberl, Michael Kurowski, Schlomo Staszewski.   

Abstract

We describe an HIV/HCV coinfected patient with liver cirrhosis, who experienced severe CNS side-effects during efavirenz-based HIV therapy. Plasma levels of efavirenz were 10 times the upper limit and remained elevated (at twice the upper limit) 4 weeks after cessation of therapy. Efavirenz resistance (K103N) developed and was probably due to 'functional' monotherapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16012018     DOI： 10.1080/00365540410020901

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  8 in total

Review 1.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.

Authors:  Emilio L Streck; Giselli Scaini; Gislaine T Rezin; Jeverson Moreira; Celine M Fochesato; Pedro R T Romão
Journal:  Metab Brain Dis       Date:  2008-09-24       Impact factor: 3.584

Review 3.  Neuropsychiatric Effects of HIV Antiviral Medications.

Authors:  Glenn J Treisman; Olivia Soudry
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

4.  Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.

Authors:  Urs Duthaler; Fabio Bachmann; Claudia Suenderhauf; Tanja Grandinetti; Florian Pfefferkorn; Manuel Haschke; Petr Hruz; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Clin Pharmacokinet       Date:  2022-05-16       Impact factor: 5.577

5.  Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice.

Authors:  Pedro R T Romão; Joelson C Lemos; Jeverson Moreira; Gisele de Chaves; Morgana Moretti; Adalberto A Castro; Vanessa M Andrade; Carina R Boeck; João Quevedo; Elaine C Gavioli
Journal:  Neurotox Res       Date:  2009-12-10       Impact factor: 3.911

6.  Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.

Authors:  Sofia A Pereira; Umbelina Caixas; Teresa Branco; Isabel Germano; Fátima Lampreia; Ana L Papoila; Emília C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2008-06-09       Impact factor: 4.335

Review 7.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 8.  HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

Authors:  Martin Vogel; Mark Nelson
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.